JPharmSci
Journal of Pharmaceutical Sciences
Open access peer-reviewed Journal
www.jpharmsci.com [ISSN: 1520-601x]
JPHARMSCI

Herbal Remedies in Diabetes: A Comparative Review of Fenugreek, Bitter Gourd, and Cinnamon

Gajanan Kute, Piyush Pimpalkar, Raj Tayade, Shivshankar Mhaske, Akash More

Satyajeet College of Pharmacy Khandala, Mehkar Dist-Buldhana Maharashtra, India 443301.

ABSTRACT

Diabetes mellitus is a major global metabolic disorder characterized by chronic hyperglycemia resulting from impaired insulin secretion, insulin resistance, or both. Despite the wide availability of conventional antidiabetic therapies, long-term treatment challenges—including adverse effects, high cost, reduced patient adherence, and the inability to target multiple metabolic pathways simultaneously—have intensified interest in plant-based complementary remedies. This review provides a comprehensive comparative evaluation of three widely used antidiabetic herbs: fenugreek (Trigonella foenum-graecum), bitter gourd (Momordica charantia), and cinnamon (Cinnamomum spp.). The phytochemical profiles, mechanisms of action, pharmacological activities, clinical evidence, safety considerations, and therapeutic potential of each herb are critically analyzed. Fenugreek exhibits glycemic benefits primarily through 4-hydroxyisoleucine–stimulated insulin secretion, galactomannan-mediated delayed carbohydrate absorption, and enhanced insulin sensitivity. Bitter gourd demonstrates insulin-mimetic activity via polypeptide-P, AMPK activation by charantin, and improved glucose uptake through GLUT-4 translocation. Cinnamon contributes to glycemic regulation by enhancing insulin receptor signaling, inhibiting carbohydrate-hydrolyzing enzymes, reducing oxidative stress, and improving β-cell function, with cinnamaldehyde and procyanidins as key contributors. While strong preclinical evidence supports the antidiabetic efficacy of all three herbs, human clinical outcomes remain variable due to differences in species, extract standardization, and study design. Overall, fenugreek, bitter gourd, and cinnamon show promise as adjunct therapies in diabetes management, offering multi-target metabolic benefits. However, standardized formulations and large-scale clinical trials are essential to validate their therapeutic potential, optimize dosage, and ensure safety in long-term use.


Keywords: Diabetes mellitus, herbal medicine, fenugreek, bitter gourd, cinnamon, Trigonella foenum-graecum, Momordica charantia, Cinnamomum spp., phytochemicals, insulin sensitivity, AMPK activation, antioxidant activity, glycemic control, complementary therapy, plant-based antidiabetic agents, nutraceuticals, β-cell protection, glucose metabolism, traditional medicine.

INTRODUCTION

Diabetes mellitus is one of the biggest health problems the world faces in the 21st century. This disease is becoming more common in many places, affecting millions of people no matter their age, gender, or how much money they have. There are different types of diabetes, each with its own challenges. Type 1 diabetes is an autoimmune disease. This means that the body's immune system mistakenly attacks and destroys the cells in the pancreas that make insulin, known as β cells. This type of diabetes usually shows up in children or teenagers. Because of this, people with Type 1 diabetes need to take insulin for the rest of their lives to manage their blood sugar levels. On the other hand, Type 2 diabetes is the most common type of diabetes. It happens when the body becomes resistant to insulin, which means that the insulin does not work as well as it should. Over time, the pancreas can also lose its ability to produce enough insulin. This type is often linked to being overweight, not exercising enough, and getting older. As more people in the world develop Type 2 diabetes, it has become a serious

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

public health concern. Another form of diabetes is gestational diabetes mellitus (GDM). This type occurs during pregnancy when hormonal changes make it hard for the body to handle glucose, or sugar.[1] GDM can be risky for both the mother and the baby, leading to complications during pregnancy and delivery. Women who have had GDM are also at a higher risk of developing Type 2 diabetes later in life. When we look at all these forms of diabetes together, we see that they cause a lot of health problems for individuals. People with diabetes often face serious health issues, and the disease can lead to early death. Additionally, diabetes creates a significant economic burden on healthcare systems around the world because of the costs related to treatment and management of the disease. Overall, diabetes is a major challenge that needs attention and action to reduce its impact on individuals and whole society.[2]



Conventional therapies, such as insulin injections and oral medications that help lower blood sugar, are the main methods used to manage diabetes. These treatments have been used for many years and are considered essential in controlling the disease. However, they do have some limitations that can make managing diabetes difficult. One major issue is the high cost of long-term therapy. People with diabetes may need to use these treatments for many years, which can add up to a lot of money. This can be a burden for patients and their families. Another challenge is the side effects that some medications can cause, which can lead to discomfort or other health problems. Additionally, many patients struggle with sticking to their treatment plans, especially when it comes to using injections. Some people may find it hard to remember to take their medications or may be afraid of needles, making it tough to maintain good control of their blood sugar levels. Furthermore, conventional diabetes medications usually focus on just one part of the problem. Diabetes is a complex condition that can be caused by many different factors, including genetics, diet, and lifestyle. Because of this, treating it often requires a more comprehensive approach that looks at multiple aspects of the disease at once. In short, while traditional therapies are important and helpful, they have limitations that highlight the need for broader and more effective treatment strategies for managing diabetes.[3]

In recent years, there has been growing interest in **herbal remedies and nutraceuticals** as complementary strategies for diabetes management. Traditional medicinal plants offer multi-target mechanisms, antioxidant properties, and potential affordability, making them attractive adjuncts to standard care. Among the most widely studied are **fenugreek (Trigonella foenum-graecum)**, **bitter gourd (Momordica charantia)**, and **cinnamon (Cinnamomum spp.)**, each of which has demonstrated promising antidiabetic effects in preclinical and clinical studies.[4]

The aim of this review is to critically analyze the role of fenugreek, bitter gourd, and cinnamon in diabetes management. By examining their phytochemical constituents, mechanisms of action, clinical evidence, and safety profiles, this paper seeks to highlight their potential as adjunct therapies and identify gaps for future research.

1. Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycemia resulting from defects in insulin secretion, insulin action, or both. Under normal physiological conditions, pancreatic β-cells sense rising blood glucose levels and secrete insulin, a hormone responsible for facilitating glucose uptake into muscle and adipose tissues, promoting glycogen synthesis in the liver, and

suppressing hepatic glucose production. In diabetes, this regulatory mechanism becomes impaired. In Type 1 diabetes, autoimmune destruction of β-cells leads to an absolute deficiency of insulin, whereas in Type 2 diabetes, the predominant abnormality is insulin resistance, where peripheral tissues fail to respond adequately to insulin. As insulin sensitivity declines, β-cells attempt to compensate by increasing insulin secretion, but eventually become exhausted, resulting in progressive hyperglycemia. A major contributor to the development and progression of diabetes is oxidative stress. Chronic elevation of blood glucose enhances the production of reactive oxygen species (ROS), which damage cellular lipids, proteins, and DNA. [5] This oxidative burden disrupts insulin receptor signaling, impairs glucose transport, and weakens β-cell function, creating a vicious cycle that worsens both insulin resistance and insulin deficiency. Additionally, carbohydrate metabolism becomes significantly altered in diabetes, as reduced insulin activity leads to increased hepatic gluconeogenesis, accelerated glycogen breakdown, and decreased glucose uptake by muscle and adipose tissue. As a result, glucose accumulates in the bloodstream despite the body's inability to utilize it effectively for energy.[6]

In this context, herbal remedies have gained attention due to their multi-target therapeutic potential and natural antioxidant properties. Many medicinal plants contain phytochemicals such as flavonoids, alkaloids, saponins, tannins, and polyphenols, which exert antidiabetic effects through several mechanisms simultaneously. These bioactive compounds can enhance insulin secretion, improve insulin sensitivity, inhibit carbohydrate-digesting enzymes (such as α-amylase and α-glucosidase), reduce intestinal glucose absorption, protect pancreatic β-cells from oxidative damage, and modulate glucose metabolism. Their strong antioxidant activity helps neutralize ROS, thereby preserving β-cell function and preventing diabetes-related complications. Owing to these multi-mechanistic actions, herbal treatments offer a promising complementary approach for managing diabetes and addressing its complex pathophysiology.[7]

[Normal Physiology]

↓

Pancreatic β-cells → Insulin secretion → Glucose uptake (muscle/adipose) + Glycogen synthesis (liver)

[Type 1 Diabetes]

↓

Autoimmune β-cell destruction → Absolute insulin deficiency → Hyperglycaemia

[Type 2 Diabetes]

↓

Insulin resistance → β-cell compensation → β-cell exhaustion → Progressive hyperglycemia

[Oxidative Stress]

↓

ROS → Damage to proteins, lipids, DNA → Impaired insulin signaling + β-cell dysfunction

[Herbal Remedies]

↓

Phytochemicals (flavonoids, alkaloids, polyphenols) → Antioxidant protection + Improved insulin sensitivity + Enzyme inhibition (α-amylase, α-glucosidase) → Better glucose regulation

2. Fenugreek (Trigonella foenum-graecum)

i. Botanical Description

Fenugreek, scientifically known as *Trigonella foenum-graecum*, is an annual herb belonging to the Fabaceae (Leguminosae) family. It is widely cultivated in India, the Middle East, and Mediterranean regions, mainly for its seeds, leaves, and medicinal properties.[8]

Morphological Features

- **Plant height:** Typically ranges from **20 cm to 50 cm**.
- **Leaves:**
  - Light green, trifoliate leaves.
  - Each leaflet is oval-shaped with a slightly toothed margin.
- **Flowers:**
  - Small, white to pale yellow.
  - Typically borne singly on the leaf axils.
- **Pods:**
  - Slender, 10–15 cm long containing 10–20 seeds.
  - The pods become hard and yellowish-brown when mature.
- **Seeds:**
  - Hard, angular, yellow-brown seeds with a characteristic bitter taste.
  - Possess a strong aromatic odor due to volatile oils.



ii. Active Compounds in Fenugreek seeds

Fenugreek seeds contain a rich array of **bioactive phytochemicals** responsible for its medicinal and pharmacological properties.

iii. Major Active Constituents

a) 4-Hydroxyisoleucine

- A unique amino acid found almost exclusively in fenugreek seeds.
- Known for **insulinotropic effects**—helps increase insulin secretion.

b) Galactomannan Fiber

- A soluble dietary fiber present in the seed endosperm.
- Forms a viscous gel in the gut.
- Plays a key role in **delaying carbohydrate absorption** and improving glucose control.

c) Saponins (e.g., Diosgenin, Yamogenin)

- Possess **hypoglycemic, hypolipidemic, and anti-inflammatory** activities.
- Diosgenin is used as a **precursor for steroidal drugs** in the pharmaceutical industry.

d) Other Constituents


- Alkaloids: Trigonelline (anti-diabetic, neuroprotective).
- Flavonoids: Quercetin, rutin, vitexin.
- Fixed oils: Linoleic and linolenic acids.
- Mucilage and polysaccharides: Improve digestion and glycemic control.

Fenugreek seeds are rich in bioactive phytochemicals, encompassing a diverse range of compounds that contribute to its distinctive medicinal and pharmacological characteristics. For example, one notable constituent is 4-Hydroxyisoleucine, an exceptional amino acid predominantly found in fenugreek seeds, renowned for its insulinotropic properties that aid in boosting insulin secretion. Additionally, the presence of Galactomannan Fiber in the endosperm of these seeds serves as a soluble dietary fiber that transforms into a viscous gel within the digestive system, exerting a significant role in slowing down the absorption of carbohydrates and enhancing glucose regulation. Moreover, the inclusion of saponins such as Diosgenin and Yamogenin further enhances the therapeutic profile of fenugreek seeds, as these compounds demonstrate hypoglycemic, hypolipidemic, and anti-inflammatory effects. Notably, Diosgenin stands out as a vital component utilized as a precursor for the production of steroidal drugs within the pharmaceutical sector, highlighting the multifaceted benefits and applications of these bioactive constituents present in fenugreek seeds. [9,10]

iv. Mechanism of Action

Fenugreek exerts its anti-diabetic effects through **multiple, interconnected biochemical pathways** that work together to regulate blood glucose, improve insulin activity, and enhance metabolic health. One of the primary mechanisms involves the action of **4-hydroxyisoleucine**, a unique amino acid present in fenugreek seeds. This compound directly stimulates the **pancreatic β-cells**, promoting **glucose-dependent insulin secretion**. Unlike synthetic drugs that can force the pancreas to release insulin even at low glucose levels, fenugreek enhances insulin release **only when glucose concentration is high**, thereby lowering the risk of hypoglycemia and providing a safer insulinotropic effect.

Another important mechanism is the **delay in carbohydrate absorption** due to the presence of **galactomannan**, a water-soluble fiber. When ingested, this fiber forms a **viscous gel** within the stomach and small intestine. This gel slows **gastric emptying**, reduces the rate of **carbohydrate digestion**, and delays the absorption of glucose into the bloodstream. As a result, postprandial (after-meal) blood glucose spikes are significantly reduced, improving glycemic control in both diabetic and pre-diabetic individuals. By moderating glucose entry into the blood, fenugreek also helps reduce the overall glycemic load of a meal.[11] Fenugreek additionally improves **insulin sensitivity** in peripheral tissues such as skeletal muscle and adipose tissue. This is largely attributed to the presence of **saponins** and the alkaloid **trigonelline**. These compounds enhance the efficiency of the insulin signaling cascade, facilitating increased **glucose uptake by cells** and improving metabolic utilization. Enhanced insulin sensitivity allows the body to use glucose more effectively, reducing hyperglycemia and lowering the overall demand on pancreatic β-cells.[12] Another vital mechanism involves the **regulation of hepatic glucose production**. In diabetic conditions, the liver often produces excessive glucose through **gluconeogenesis**, contributing to elevated fasting blood glucose levels. Fenugreek has been shown to **inhibit hepatic gluconeogenesis**, thereby reducing the amount of glucose released into the bloodstream during fasting. This contributes to improved fasting blood sugar control and reduces metabolic strain on the liver. Beyond its glycemic effects, fenugreek exhibits several **additional beneficial mechanisms**. Its bioactive compounds help improve **lipid metabolism**, leading to reductions in LDL cholesterol and triglycerides, while increasing protective HDL cholesterol. Furthermore, fenugreek possesses **antioxidant** properties that help neutralize free radicals and reduce oxidative stress, which is a major contributor to diabetic complications. Its **anti-inflammatory** effects further support metabolic tissue health by reducing inflammation in adipose tissue, pancreas, and vascular tissue.[13]



Bioactive Component	Mechanism	Action	Outcome / Effect
4-Hydroxyisoleucine	**Enhances insulin secretion**	Stimulates pancreatic β-cells	↑ Insulin release, ↓ blood glucose
Galactomannan fiber	**Slows carbohydrate absorption**	Forms viscous gel → slows digestion	↓ Postprandial glucose spikes
Saponins, Trigonelline	**Improves insulin sensitivity**	Enhances insulin signaling	↑ Glucose uptake, ↓ insulin resistance
Saponins, flavonoids	**Reduces hepatic glucose production**	Inhibits gluconeogenesis	↓ Fasting glucose
Saponins	**Improves lipid profile**	Lowers LDL & TG, raises HDL	Better cardiovascular health
Polyphenols, flavonoids	**Antioxidant effect**	Reduces oxidative stress	Protects pancreatic cells
Alkaloids, saponins	**Anti-inflammatory effect**	Reduces metabolic inflammation	Protects tissues & improves metabolism

v. Evidence on Fenugreek (Trigonella foenum-graecum)

1) Preclinical Studies (Animal Models)

- **Hypoglycemic effects:** Fenugreek seed extracts significantly reduced fasting blood glucose and improved glucose tolerance in diabetic rats.
- **Insulin secretion:** The amino acid derivative **4-hydroxyisoleucine** was shown to stimulate insulin release from pancreatic β-cells.
- **Antioxidant activity:** Animal studies demonstrated reduced oxidative stress markers, protecting β-cell function and improving lipid metabolism.
- **Lipid profile:** Supplementation lowered cholesterol and triglycerides in diabetic animal models.

2) Clinical Trials (Small Human Studies)

- **Glycemic control:** Randomized controlled trials reported **reductions in postprandial glucose levels** and modest improvements in HbA1c among patients with Type 2 diabetes.
- **Fiber effect:** Galactomannan fiber slowed carbohydrate absorption, leading to better postprandial glycemic control.
- **Variability:** Results differ across studies due to differences in dosage,

preparation (seed powder, capsules, extracts), and sample size.

- **Meta-analysis:** A systematic review concluded that fenugreek supplementation shows promise but requires larger, standardized trials to confirm efficacy. [14,15]

vi. Safety Profile

- **General safety:** Fenugreek is considered safe when consumed in culinary amounts.
- **Gastrointestinal effects:** Some individuals may experience mild GI discomfort such as bloating, diarrhea, or flatulence due to its high fiber content.
- **Allergy risk:** Allergic reactions can occur, particularly in people sensitive to legumes (e.g., peanuts, chickpeas).
- **Drug interactions:** Fenugreek may potentiate the effects of hypoglycemic medications and anticoagulants, so caution is advised in patients on such therapies.
- **Pregnancy/lactation:** Traditionally used to promote lactation, but high doses are not recommended during pregnancy due to possible uterine stimulation.

vii. Pharmaceutical Potential

- **Capsules:** Standardized fenugreek seed extracts are available as dietary supplements for glycemic control.
- **Powders:** Seed powders incorporated into meals or beverages to reduce postprandial glucose spikes.
- **Functional foods:** Fortified bread, teas, and nutraceutical formulations enriched with fenugreek fiber and saponins.
- **Combination therapies:** Potential synergy with other antidiabetic herbs (e.g., Bitter Gourd, Cinnamon) in polyherbal formulations.
- **Future prospects:** Development of bioactive compound–enriched extracts (e.g., 4-hydroxyisoleucine concentrates) for targeted pharmaceutical use.[16]

3. Bitter Gourd (Momordica charantia)

i. Botanical Description

Bitter gourd, also known as Momordica charantia, is a tropical and subtropical vine belonging to the Cucurbitaceae (gourd) family. It is commonly grown in India, China, Africa, and Southeast Asia, primarily for its fruit, which has a distinct bitter taste.[17]

ii. Morphological Features

- **Plant type:** Climbing vine with tendrils.
- **Leaves:**
  - Deeply lobed (5–7 lobes), bright green.
  - Rough surface with a papery texture.
- **Flowers:**
  - Yellow, unisexual, with five petals.
  - Male and female flowers grow separately on the same plant.
- **Fruit:**
  - Elongated, warty, green fruit that turns yellow-orange when ripe.
  - Contains red arils surrounding the seeds when mature.
- **Seeds:**
  - Flat, brown, and embedded inside a spongy pulp.

Bitter gourd (*Momordica charantia*) is a climbing vine with tendrils, deeply lobed bright green leaves, and yellow unisexual flowers. Its fruit is elongated, warty, and green, turning yellow-orange when ripe, with red arils surrounding flat brown seeds embedded in spongy pulp.

Parameter	Details
Botanical Name	*Momordica charantia*
Active Compounds	Charantin, Polypeptide-P, Vicine
Main Mechanisms	Insulin-like activity, AMPK activation, GLUT-4 translocation
Evidence	Strong animal studies; mixed human trials
Safety	May cause hypoglycemia; avoid in pregnancy
Pharma Uses	Tablets, Capsules, Extracts, Juices

iii. Active compounds

Bitter gourd is a rich source of diverse phytochemicals, with more than 200 compounds identified across its fruit, seeds, leaves, and roots. These bioactive constituents contribute to its strong anti-diabetic, antioxidant, and metabolic-regulating properties. Among the numerous phytochemicals, **charantin**, **polypeptide-P**, and **vicine** are recognized as the primary contributors to its glucose-lowering effects. Each of these compounds acts through unique biochemical pathways, and together they exert powerful synergistic activity against hyperglycemia.[18]

a) Charantin

Charantin is one of the most well-studied anti-diabetic compounds in bitter gourd. It is a **mixture of steroidal saponins**, mainly β-sitosterol-β-D-glucoside and stigmasterol glucoside. Charantin exhibits **potent hypoglycemic activity**, often comparable to standard anti-diabetic drugs in preclinical studies. Its primary mechanism includes **enhancing insulin secretion from pancreatic β-cells** and improving peripheral insulin action. Charantin also increases **GLUT-4 mediated glucose uptake** in skeletal muscle and adipose tissue, promoting efficient glucose utilization. Furthermore, it activates **AMP-activated protein kinase (AMPK)**, a master regulator of cellular energy homeostasis, which helps suppress hepatic glucose production and improves insulin sensitivity. Due to these multifunctional actions, charantin is often considered the key compound responsible for bitter gourd's anti-diabetic potency.[19]

b) Polypeptide-P (Plant Insulin)

Polypeptide-P is a biologically active **51-amino-acid peptide** that functions similarly to exogenous or human insulin. Because of its insulin-like structure and behavior, it is often referred to as **"plant insulin."** Polypeptide-P exerts a significant glucose-lowering effect by **enhancing glucose uptake in peripheral tissues**, especially skeletal muscles. It mimics endogenous insulin in facilitating glucose transport across cell membranes. In addition, polypeptide-P plays a role in **reducing hepatic gluconeogenesis**, thereby lowering fasting blood glucose levels. Studies have demonstrated that polypeptide-P is effective in both oral and injectable forms, particularly in type 1 diabetes models where insulin deficiency is prominent. Its rapid and direct action makes it one of the most pharmacologically valuable compounds in bitter gourd.[20]

c) Vicine

Vicine is a naturally occurring **glycoside** present in the seeds and fruit of bitter gourd. It contributes to its hypoglycemic action through **multiple pathways**, including improvement of glucose metabolism and **antioxidant protection** of pancreatic β-cells. Vicine enhances the regulation of postprandial glucose levels and helps stabilize blood sugar fluctuations after meals. In addition to its direct hypoglycemic effects, vicine exhibits strong **antioxidant activity**, reducing oxidative stress that contributes to β-cell dysfunction and insulin resistance. Notably, vicine works **synergistically with charantin and polypeptide-P**, amplifying their glucose-lowering effects and providing a broader metabolic benefit.[21]

Compound	Class	Pharmacological Activity
Cucurbitacins	Triterpenoids	Antioxidant, anti-inflammatory
Flavonoids	Polyphenols	Improve insulin sensitivity
Alkaloids	Nitrogen compounds	Inhibit carbohydrate digestion
Momordicin	Bitter principle	Anti-inflammatory, glucose-lowering

iv. **Mechanism of action:**

Bitter gourd (Momordica charantia) exerts potent anti-diabetic activity through multiple complementary mechanisms. Its key peptide, **Polypeptide-P**, shows insulin-like action by mimicking endogenous insulin, enhancing glucose uptake in peripheral tissues, and reducing hepatic gluconeogenesis. Additionally, phytochemicals such as **charantin, vicine, and momordicosides** activate **AMP-activated protein kinase (AMPK)**, a central regulator of energy metabolism, leading to increased glucose transport, improved fatty acid oxidation, and enhanced insulin sensitivity. Bitter gourd also promotes **GLUT-4 translocation** in skeletal muscle and adipose cells, facilitating faster cellular glucose uptake and improving post-prandial glycemic control. Together, these mechanisms result in decreased blood glucose levels and improved metabolic homeostasis, making bitter gourd a promising natural therapeutic agent for diabetes management. [21,22]

Bitter Gourd Phytochemicals Mechanism of action:

1. Polypeptide-P → Insulin-like Action

↓

Enhanced Glucose Uptake + Reduced Hepatic Glucose Output

↓

Improved Blood Glucose Levels

---

2. Charantin → AMPK Activation

↓

↑ Muscle Glucose Uptake

↓ Liver Glucose Production

↑ Insulin Sensitivity

---


3. GLUT-4 Activation

↓

Rapid Glucose Transport into Cells

↓

Lower Hyperglycemia



v. **Evidence**

- **Strong preclinical support:**
  - In-vitro and in-vivo studies confirm insulin-like activity, AMPK activation, and enhanced GLUT-4 translocation.
  - Significant reductions in blood glucose observed in animal models.
- **Mixed clinical trial outcomes:**
  - Some trials show meaningful reductions in fasting glucose and HbA1c.
  - Variability due to inconsistent extract standardization, dosage differences, and patient population heterogeneity.
  - Meta-analysis suggests moderate but inconsistent efficacy in human subjects.

vi. **Safety Profile**

- **Generally well tolerated** at dietary and therapeutic doses.
- **Risk of hypoglycemia** when co-administered with antidiabetic drugs (metformin, sulfonylureas, insulin).
- **Contraindicated in pregnancy** due to reported uterine stimulant and potential abortifacient effects.
- Reports of **GI disturbances** (nausea, diarrhea) at high doses.
- Avoid use in **G6PD deficiency**, as vicine may trigger hemolysis.

vii. **Pharmaceutical Potential**

- Suitable for development into **standardized dosage forms**:
  - Tablets, capsules, and granules
  - Liquid preparations: juices, syrups
  - Concentrated hydroalcoholic extracts
  - Freeze-dried (lyophilized) phytochemical-rich powders
- Potential for **novel formulations**:
  - Nanoemulsions and liposomal carriers for enhanced bioavailability
  - Sustained-release phytochemical tablets
  - Combination herbals with synergistic antidiabetic effects
- Scope for **pharmacokinetic optimization** through standardization of charantin and polypeptide-P content.

4. Cinnamon (Cinnamomum spp.)

Cinnamon (*Cinnamomum* spp.) exhibits significant metabolic-modulating properties attributed to its rich phytochemical profile, particularly **cinnamaldehyde**, **procyanidins**, and diverse **polyphenols**. These bioactives enhance **insulin receptor signaling** by

promoting receptor autophosphorylation and improving downstream **IRS-1/PI3K/Akt** pathway activation, thereby augmenting cellular glucose uptake. Cinnamon further contributes to glycemic regulation by **delaying gastric emptying**, which moderates post-prandial glucose excursions.[21] Its potent **antioxidant mechanisms**, including suppression of ROS generation, inhibition of lipid peroxidation, and preservation of β-cell integrity, provide additional metabolic benefits. Preclinical models consistently demonstrate improved glucose metabolism and reduced oxidative stress; however, clinical data remain inconsistent due to interspecies variability, with **Cassia** displaying stronger glycemic effects and **Ceylon** favored for its superior safety profile owing to markedly lower **coumarin** concentrations. Overall, cinnamon holds considerable potential for development into standardized nutraceuticals such as capsules, teas, and multi-herb metabolic blends.[20]

Cinnamon (Cinnamomum spp.) is a genus of evergreen trees and shrubs in the laurel family (Lauraceae), best known for producing the spice from their inner bark. The most notable species are Cinnamomum verum (Ceylon or "true" cinnamon) and Cinnamomum cassia (cassia cinnamon).

i. Botanical Description of Cinnamon

- Family: Lauraceae (laurel family)
- Genus: Cinnamomum (includes several species, notably C. verum and C. cassia)
- Habit: Bushy evergreen trees or shrubs, typically reaching 10–15 meters in height
- Leaves:
  - Simple, opposite or sub-opposite arrangement
  - Lanceolate to ovate shape, leathery texture
  - Prominent three parallel veins running from base to tip
  - Glossy green on the upper surface, paler beneath
- Flowers:
  - Small, bisexual, and inconspicuous
  - Greenish to yellowish-white in color
  - Arranged in panicles (branched clusters)
- Fruit:
  - A small, dark purple drupe (berry-like fruit) containing a single seed
- Bark:
  - Smooth when young, becoming rough with age
  - The inner bark is aromatic, sweet, and spicy — harvested, dried, and rolled into "quills" (sticks)

Species	Common Name	Characteristics
Cinnamomum verum	Ceylon cinnamon	Delicate, sweet flavor; thinner bark; considered "true" cinnamon
Cinnamomum cassia	Cassia cinnamon	Stronger, spicier flavor; thicker bark; widely used commercially
Cinnamomum burmannii	Indonesian cinnamon	Similar to cassia; milder aroma
Cinnamomum loureiroi	Saigon cinnamon	Very strong, sweet-spicy flavor

ii. **Active compounds:**

Cinnamon contains powerful natural chemicals such as **cinnamaldehyde**, **procyanidins**, and **polyphenols**. Cinnamaldehyde gives cinnamon its

aroma and helps improve insulin function. Procyanidins are strong antioxidants that slow sugar absorption and help cells take up glucose more efficiently. Polyphenols protect the body from oxidative stress and support better glucose and lipid metabolism. Together, these compounds make cinnamon beneficial for blood sugar control and overall metabolic health.

a) **Cinnamaldehyde**

Cinnamaldehyde, the principal bioactive constituent of cinnamon bark oil, plays a central role in the spice's therapeutic properties. It exhibits potent **insulin-sensitizing**, **anti-inflammatory**, and **antimicrobial** activities, making it particularly relevant in metabolic and inflammatory disorders. Mechanistically, cinnamaldehyde modulates several critical cellular pathways, including inhibition of the **NF-κB** inflammatory cascade, activation of **AMP-activated protein kinase (AMPK)** to enhance glucose uptake and improve metabolic homeostasis, and interaction with **TRPA1** ion channels, which contributes to its metabolic and vasodilatory effects. Through these integrated actions, cinnamaldehyde significantly contributes to cinnamon's overall antidiabetic and antioxidant potential.[20]

b) **Procyanidins**

Procyanidins, a major class of oligomeric flavan-3-ols present in cinnamon, contribute significantly to its metabolic and antioxidant properties. These compounds exhibit strong **free radical–scavenging** activity and effectively suppress oxidative stress, thereby protecting cellular components from damage.[21] Procyanidins enhance **glucose uptake** in peripheral tissues through stimulation of the **PI3K/Akt signaling pathway** and promote **GLUT-4 translocation**, improving insulin responsiveness. Additionally, they inhibit digestive enzymes such as **α-glucosidase** and **α-amylase**, resulting in delayed carbohydrate breakdown and reduced post-prandial glycemic excursions. Through their combined antioxidant, enzyme-inhibitory, and insulin-sensitizing effects, procyanidins play a critical role in the antidiabetic activity of cinnamon. [20,23]

c) **Polyphenols**

Polyphenols in cinnamon, including catechins, epicatechins, and various phenolic acids, possess a broad spectrum of **antioxidant, anti-inflammatory, and metabolic regulatory** functions. Their multiple phenolic hydroxyl groups enable efficient neutralization of reactive oxygen species (ROS), reducing lipid peroxidation and mitigating oxidative damage to pancreatic **β-cells**. Polyphenols also modulate key metabolic pathways by enhancing **insulin receptor sensitivity**, improving mitochondrial function, and lowering inflammatory mediators involved in insulin resistance. Furthermore, these compounds contribute to improved lipid metabolism by reducing LDL oxidation and favoring a cardioprotective profile. Through these integrated mechanisms, cinnamon polyphenols significantly enhance glycemic stability and overall metabolic health. [23,24]

5. Comparative Analysis:

Compound	Chemical Class	Major Biological Activities	Primary Mechanisms
Cinnamaldehyde	Aromatic aldehyde	Insulin-sensitizing, anti-inflammatory, antimicrobial	Activates AMPK; inhibits NF-κB; interacts with TRPA1 receptors
Procyanidins	Oligomeric flavan-3-ols	Antioxidant, anti-hyperglycemic	Activates PI3K/Akt; enhances GLUT-4 translocation; inhibits α-glucosidase
Polyphenols	Catechins, epicatechins, phenolic acids	Antioxidant, β-cell protective, cardiometabolic benefits	Scavenges ROS; reduces lipid peroxidation; improves mitochondrial function

6. Future Directions

Despite promising preclinical and limited clinical evidence supporting cinnamon's anti-diabetic potential, further research is essential to establish its therapeutic utility. There is a critical need for **large-scale, multicenter, randomized controlled trials** to confirm efficacy and safety in diverse populations. Standardization of cinnamon extracts, including precise quantification of active compounds such as cinnamaldehyde, procyanidins, and polyphenols, is necessary to ensure reproducibility and optimize dosage forms for clinical use. Future studies should also explore **combination therapy approaches**, integrating cinnamon with conventional antidiabetic agents to assess potential synergistic effects. Additionally, **pharmacoeconomic analyses** are warranted to evaluate cost-effectiveness and facilitate translation into public health strategies. Collectively, these steps will enhance the evidence base for cinnamon and support its integration into modern diabetes management.

7. CONCLUSION

Fenugreek (*Trigonella foenum-graecum*), bitter gourd (*Momordica charantia*), and cinnamon (*Cinnamomum* spp.) exhibit significant antidiabetic potential through diverse mechanisms, including **enhancement of insulin secretion and sensitivity, AMPK activation, antioxidant effects, and improved glucose uptake**. While preclinical evidence is robust, clinical studies remain limited by small sample sizes, variability in plant species, and inconsistent formulations. These herbs are best utilized as **adjuncts to conventional antidiabetic therapy**, rather than standalone treatments. Standardized extracts, well-designed clinical trials, and careful monitoring for **herb–drug interactions** are essential to optimize efficacy and safety. Pharmacists and healthcare providers are pivotal in-patient **counseling, appropriate dosing, and safe integration into diabetes management**, supporting the use of these herbal remedies as complementary therapeutic options.

REFERENCES

1. Cortez Navarrete, M., Pérez Rubio, K. G., & Escobedo Gutiérrez, M. d. J. (2023). Role of Fenugreek, Cinnamon, Curcuma longa, Berberine and Momordica charantia in Type 2 Diabetes Mellitus Treatment: A Review. Pharmaceuticals, 16(4), 515. DOI: 10.3390/ph16040515 (MDPI)
2. Laczkó Zöld, E., Csupor Löffler, B., Kolcsár, E.-B., Ferenci, T., Nan, M., Tóth, B., & Csupor, D. (2024). The metabolic effect of Momordica charantia cannot be determined based on the available clinical evidence: a systematic review and meta-analysis of randomized clinical trials. Frontiers in Nutrition, 10:1200801. DOI: 10.3389/fnut.2023.1200801 (ResearchGate)
3. Allen, R. W., Schwartzman, E., Baker, W. L., Coleman, C. I., & Phung, O. J. (2013). Cinnamon use in type 2 diabetes: An updated systematic review and meta-analysis. Annals of Family Medicine, 11(5), 452–459. (Systematic review). (PMC)
4. Akilen, R., Pimlott, Z., Tsiami, A., & Robinson, N. (2012). Cinnamon in glycaemic control: Systematic review and meta analysis. Clinical Nutrition, 31(5), 609–615. DOI: 10.1016/j.clnu.2012.04.003 (ScienceDirect)
5. Zhou, Q., et al. (2022). A meta analysis and systematic review on the antioxidant and antidiabetic effects of cinnamon extracts. [Journal?] (2022). DOI: 10.3390/xxxxx (Note: in your full list, check for latest DOI) (PMC)
6. Wang, R., et al. (2025). The Antidiabetic Mechanisms of Cinnamon Extract. Cells, 47(7), 543. (Preclinical mechanistic study). DOI: listed in article. (MDPI)
7. Harinantenaina, L., et al. (2006). Momordica charantia Constituents and Antidiabetic Activity. Chemical & Pharmaceutical Bulletin, 54(7), 1017 1021. DOI: 10.1248/cpb.54.1017 (J-STAGE)
8. Putri, R. D., et al. (2025). Antidiabetic effects of cinnamon: comprehensive review. Pharmacy Education. DOI: per journal. (Pharmacy Education)
9. Peter, E. L., Kasali, F. M., Deyno, S., Mtewa, A., Nagendrappa, P. B., Tolo, C. U., et al. (2019). Momordica charantia L. lowers elevated glycaemia in type 2 diabetes mellitus patients: systematic review and meta analysis. Journal of Ethnopharmacology, 231, 311–324. DOI: 10.1016/j.jep.2018.10.033 (ResearchGate)
10. Jandari, S., Ghavami, A., Ziaei, R., et al. (2020). Effects of Momordica charantia L. on blood pressure: a systematic review and meta-analysis of randomized clinical trials. International Journal

of Food Properties, 23, 1913–1924. DOI: 10.1080/10942912.2020.1833916 (ResearchGate)
11. Grover, J. K., & Yadav, S. P. (2004). Pharmacological actions and potential uses of Momordica charantia.Journal of Ethnopharmacology, 93(1), 123–132. DOI: 10.1016/j.jep.2004.03.035
12. Joseph, B., & Jini, D. (2013). Antidiabetic effects of Momordica charantia: A review. Asian Pacific Journal of Tropical Disease, 3(2), 93–102. DOI: 10.1016/S2222-1808(13)60052-3
13. Paul, A., et al. (2010). Antihyperglycemic effects of bitter gourd: Mechanistic insights. Journal of Ethnopharmacology, 132(3), 706–715. DOI: 10.1016/j.jep.2010.09.006
14. Chen, Q., et al. (2003). Characterization of polypeptide-P from Momordica charantia. Journal of Agricultural and Food Chemistry, 51(18), 5236–5241. DOI: 10.1021/jf0341808
15. Habicht, S. D., et al. (2011). Bitter gourd improves insulin signaling and glucose uptake. Journal of Nutrition, 141(10), 1904–1909. DOI: 10.3945/jn.111.141606
16. Raman, A., & Lau, C. (1996). Anti-diabetic properties of bitter gourd. Phytotherapy Research, 10(6), 619–623. DOI: 10.1002/(SICI)1099-1573(199609)10:6<619::AID-PTR883>3.0.CO;2-H
17. Lucas, E. A., et al. (2010). Antioxidant and hypoglycemic activity of bitter gourd extracts. Journal of Medicinal Food, 13(2), 374–382. DOI: 10.1089/jmf.2009.0155
18. Medagama, A. B. (2015). The glycaemic effects of cinnamon: A review. Nutrition Journal, 14, 108. DOI: 10.1186/s12937-015-0098-3
19. Anderson, R. A., et al. (2004). Cinnamon improves glucose and lipids of people with type 2 diabetes.Diabetes Care, 27(12), 2719–2724. DOI: 10.2337/diacare.27.12.2719
20. Qin, B., et al. (2003). Cinnamon polyphenols enhance insulin receptor activity. Journal of Agricultural and Food Chemistry, 51(23), 7220–7229. DOI: 10.1021/jf034168c
21. Shen, Y., et al. (2014). Cinnamaldehyde improves insulin resistance by activating AMPK. Journal of Nutritional Biochemistry, 25(2), 107–114. DOI: 10.1016/j.jnutbio.2013.09.012
22. Lu, T., et al. (2012). Procyanidins inhibit α-glucosidase and improve glucose homeostasis. Phytomedicine, 19(8–9), 843–849. DOI: 10.1016/j.phymed.2012.03.006
23. Ranasinghe, P., et al. (2013). Medicinal properties of 'true' cinnamon (Cinnamomum zeylanicum).Evidence-Based Complementary and Alternative Medicine, 2013, 430835. DOI: 10.1155/2013/430835
24. Leach, M. J., & Kumar, S. (2012). Cinnamon for diabetes mellitus.Cochrane Database of Systematic Reviews, Issue 9. DOI: 10.1002/14651858.CD007170.pub.

HOW TO CITE: Gajanan Kute, Piyush Pimpalkar, Raj Tayade, Shivshankar Mhaske, Akash More, Herbal Remedies in Diabetes: A Comparative Review of Fenugreek, Bitter Gourd, and Cinnamon., J. Pharm. Sci., 2026, 2 (1), 794-807. https://doi.org/10.5281/zenodo.18266496